Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) EPS (Weighted Average and Diluted) (2021 - 2025)

Medicinova (MNOV) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.05 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$0.05 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.24, a N/A change, with the full-year FY2025 number at -$0.24, down 4.35% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.05 for Q4 2025 at Medicinova, up from -$0.07 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q3 2023 to a low of -$0.09 in Q2 2021.
  • A 5-year average of -$0.06 and a median of -$0.06 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 85.71% in 2023, then crashed 500.0% in 2024.
  • Medicinova's EPS (Weighted Average and Diluted) stood at -$0.04 in 2021, then crashed by 75.0% to -$0.07 in 2022, then soared by 42.86% to -$0.04 in 2023, then tumbled by 50.0% to -$0.06 in 2024, then increased by 16.67% to -$0.05 in 2025.
  • Per Business Quant, the three most recent readings for MNOV's EPS (Weighted Average and Diluted) are -$0.05 (Q4 2025), -$0.07 (Q3 2025), and -$0.07 (Q2 2025).